1. Home
  2. CRDL vs KNDI Comparison

CRDL vs KNDI Comparison

Compare CRDL & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • KNDI
  • Stock Information
  • Founded
  • CRDL 2017
  • KNDI 2002
  • Country
  • CRDL Canada
  • KNDI China
  • Employees
  • CRDL N/A
  • KNDI N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • KNDI Auto Manufacturing
  • Sector
  • CRDL Health Care
  • KNDI Consumer Discretionary
  • Exchange
  • CRDL Nasdaq
  • KNDI Nasdaq
  • Market Cap
  • CRDL 126.5M
  • KNDI 109.2M
  • IPO Year
  • CRDL N/A
  • KNDI N/A
  • Fundamental
  • Price
  • CRDL $1.09
  • KNDI $1.36
  • Analyst Decision
  • CRDL Strong Buy
  • KNDI
  • Analyst Count
  • CRDL 2
  • KNDI 0
  • Target Price
  • CRDL $9.00
  • KNDI N/A
  • AVG Volume (30 Days)
  • CRDL 749.6K
  • KNDI 214.1K
  • Earning Date
  • CRDL 11-13-2025
  • KNDI 08-19-2025
  • Dividend Yield
  • CRDL N/A
  • KNDI N/A
  • EPS Growth
  • CRDL N/A
  • KNDI N/A
  • EPS
  • CRDL N/A
  • KNDI N/A
  • Revenue
  • CRDL N/A
  • KNDI $104,035,613.00
  • Revenue This Year
  • CRDL N/A
  • KNDI N/A
  • Revenue Next Year
  • CRDL N/A
  • KNDI N/A
  • P/E Ratio
  • CRDL N/A
  • KNDI N/A
  • Revenue Growth
  • CRDL N/A
  • KNDI N/A
  • 52 Week Low
  • CRDL $0.77
  • KNDI $0.89
  • 52 Week High
  • CRDL $2.54
  • KNDI $2.07
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 44.63
  • KNDI 47.20
  • Support Level
  • CRDL $1.04
  • KNDI $1.35
  • Resistance Level
  • CRDL $1.10
  • KNDI $1.45
  • Average True Range (ATR)
  • CRDL 0.06
  • KNDI 0.07
  • MACD
  • CRDL 0.01
  • KNDI -0.02
  • Stochastic Oscillator
  • CRDL 38.24
  • KNDI 9.52

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

Share on Social Networks: